AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25121977 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled data
Number of subjects: 0
Study 20661161 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast baths
Number of subjects: 26
Study 20661161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice baths
Number of subjects: 26
Study 20661161 — intervention group
Group type: COMPARATOR
Intervention: Control (no recovery)
Number of subjects: 26
Study 19395584 — intervention group
Group type: EXPERIMENTAL
Intervention: CD-NP (novel chimeric natriuretic peptide)
Number of subjects: 0
Study 17495560 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated medical and social care management model
Number of subjects: 0
Study 17495560 — intervention group
Group type: COMPARATOR
Intervention: Purely social model
Number of subjects: 0
Study 15491273 — intervention group
Group type: EXPERIMENTAL
Intervention: Faces of actors who performed trait-implying behaviors
Number of subjects: 120
Study 15491273 — intervention group
Group type: COMPARATOR
Intervention: Control faces (not specified in detail)
Number of subjects: 120
Study 11208829 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (9 microg/kg/d)
Number of subjects: 71
Study 11208829 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (18 microg/kg/d)
Number of subjects: 71
Study 11208829 — intervention group
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (both doses)
Number of subjects: 71
Study 9624068 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at home care
Number of subjects: 486
Study 7848401 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet (55% carbohydrates, 30% fats)
Number of subjects: 42
Study 7848401 — intervention group
Group type: COMPARATOR
Intervention: High-monounsaturated-fat diet (40% carbohydrates, 45% fats)
Number of subjects: 42
Study 3296163 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin and gentamicin (C + G)
Number of subjects: 72
Study 3296163 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (Ce)
Number of subjects: 72
Study 30307130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical porcine bone (cort)
Number of subjects: 90
Study 30307130 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenated corticocancellous porcine bone (coll)
Number of subjects: 90
Study 30307130 — intervention group
Group type: COMPARATOR
Intervention: Control group (ctrl)
Number of subjects: 90
Study 27343780 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.15mg) with 0.33% ropivacaine (30mL)
Number of subjects: 53
Study 27343780 — intervention group
Group type: COMPARATOR
Intervention: 0.33% ropivacaine (30mL) alone
Number of subjects: 53
Study 24766166 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly telephone calls
Number of subjects: 30
Study 24766166 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text messages
Number of subjects: 30
Study 24766166 — intervention group
Group type: EXPERIMENTAL
Intervention: Both telephone calls and text messages
Number of subjects: 30
Study 22321155 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) combined with exercise training (2 days a week)
Number of subjects: 30
Study 20219265 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg every other week)
Number of subjects: 96
Study 20219265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 19010769 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoural chemotherapy
Number of subjects: 40
Study 19010769 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy
Number of subjects: 40
Study 16160615 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/d, mean dose at endpoint 8.75 mg/day)
Number of subjects: 48
Study 16160615 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (4 mg/d, mean dose at endpoint 2.88 mg/d)
Number of subjects: 48
Study 16160615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12893107 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment of depression in patients with diabetes
Number of subjects: 0
Study 12893107 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy and/or psychopharmacologic treatment
Number of subjects: 0
Study 10805839 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol
Number of subjects: 101
Study 10805839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 8857250 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemiluminescent immunoassay (CLIA) for thyroid stimulating hormone (TSH) and free-T4
Number of subjects: 316
Study 8857250 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemiluminescent immunoassay (CLIA) for intact-parathyroid hormone (PTH)
Number of subjects: 316
Study 8857250 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CLIA for intact-PTH with serum calcium levels and clinical conditions
Number of subjects: 316
Study 8857250 — intervention group
Group type: COMPARATOR
Intervention: Immunoradiometric immunoassay (IRMA) for TSH and PTH
Number of subjects: 316
Study 1825315 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 infection preceding HBV infection
Number of subjects: 134
Study 1825315 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated HIV-1-infected persons
Number of subjects: 134
Study 1825315 — intervention group
Group type: COMPARATOR
Intervention: HIV-1-infected persons who failed to respond to vaccination
Number of subjects: 134
Study 1825315 — intervention group
Group type: COMPARATOR
Intervention: HIV-1-infected persons who received vaccine doses at the time of new HBV infection
Number of subjects: 134
Study 1825315 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 infection
Number of subjects: 134
Study 1825315 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated HIV-1-negative men
Number of subjects: 134
Study 6395212 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant cyclophosphamide, vincristine, prednisone (CVP) chemotherapy with extended field radiotherapy (RT) in stage I patients.
Number of subjects: 180
Study 6395212 — intervention group
Group type: COMPARATOR
Intervention: Extended field radiotherapy (RT) in stage II patients.
Number of subjects: 180
Study 6395212 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nodal irradiation in stage II patients.
Number of subjects: 180
Study 6395212 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapeutic strategy with alternating RT and CT tested in a pilot study.
Number of subjects: 180
Study 31722952 — intervention group
Group type: EXPERIMENTAL
Intervention: My Breathing Matters (MBM) digital self-management intervention
Number of subjects: 88
Study 31722952 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 88
Study 29415576 — intervention group
Group type: EXPERIMENTAL
Intervention: History of childhood sexual abuse
Number of subjects: 1181
Study 29415576 — intervention group
Group type: EXPERIMENTAL
Intervention: Low religious participation
Number of subjects: 1181
Study 29415576 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1181
Study 26704625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish before rice (FR)
Number of subjects: 22
Study 26704625 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat before rice (MR)
Number of subjects: 22
Study 26704625 — intervention group
Group type: COMPARATOR
Intervention: Rice before fish (RF)
Number of subjects: 22
Study 25315941 — intervention group
Group type: EXPERIMENTAL
Intervention: Icy normal saline group (1,000 mL of 4°C normal saline intravenously)
Number of subjects: 45
Study 25315941 — intervention group
Group type: COMPARATOR
Intervention: Control group (ice bag on head)
Number of subjects: 45
Study 25315941 — intervention group
Group type: EXPERIMENTAL
Intervention: Icy normal saline group
Number of subjects: 45
Study 25315941 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 22305917 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-mcg buccal misoprostol
Number of subjects: 1122
Study 22305917 — intervention group
Group type: COMPARATOR
Intervention: 800-mcg buccal misoprostol
Number of subjects: 1122
Study 21142988 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based orientation approach
Number of subjects: 54
Study 21142988 — intervention group
Group type: COMPARATOR
Intervention: Text-based electronic information sheets
Number of subjects: 54
Study 17962589 — intervention group
Group type: EXPERIMENTAL
Intervention: >=50% LDL-C reduction
Number of subjects: 4731
Study 17962589 — intervention group
Group type: COMPARATOR
Intervention: No change or increase in LDL-C
Number of subjects: 4731
Study 15691349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (200 mg tablets, twice daily)
Number of subjects: 11
Study 15691349 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine digluconate (0.1% mouth rinse)
Number of subjects: 11
Study 15691349 — intervention group
Group type: COMPARATOR
Intervention: Saline (negative control mouth rinse)
Number of subjects: 11
Study 14569174 — intervention group
Group type: EXPERIMENTAL
Intervention: F0 test
Number of subjects: 36
Study 14569174 — intervention group
Group type: COMPARATOR
Intervention: F+20 test
Number of subjects: 36
Study 14569174 — intervention group
Group type: EXPERIMENTAL
Intervention: PM image
Number of subjects: 36
Study 10652038 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-magnesium citrate (KMgCit; 42 mEq K, 21 mEq Mg, and 63 mEq citrate/day)
Number of subjects: 60
Study 10652038 — intervention group
Group type: COMPARATOR
Intervention: Potassium chloride (42 mEq/day)
Number of subjects: 60
Study 8882672 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple session intervention
Number of subjects: 318
Study 8882672 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session intervention
Number of subjects: 318
Study 8882672 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 318
Study 1944425 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of oral milrinone daily
Number of subjects: 1088
Study 1944425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1088
Study 6494106 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss intervention
Number of subjects: 52
Study 6494106 — intervention group
Group type: COMPARATOR
Intervention: Na:K intervention
Number of subjects: 52
Study 29688772 — intervention group
Group type: EXPERIMENTAL
Intervention: Scripted lesson plans and supporting activities as part of the revised sexuality education curriculum.
Number of subjects: 0
Study 29688772 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 0
Study 28511642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Walk@WorkSpain (W@WS) program, n = 129 (87 female)
Number of subjects: 264
Study 28511642 — intervention group
Group type: COMPARATOR
Intervention: Active Comparison Group (A-CG) - pedometer, paper diary, and self-reported sitting time, n = 135 (84 female)
Number of subjects: 264
Study 28511642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG)
Number of subjects: 264
Study 26346122 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (hyaluronic acid injection + low-level laser therapy)
Number of subjects: 70
Study 26346122 — intervention group
Group type: COMPARATOR
Intervention: Protocol A (sham light source + saline injection)
Number of subjects: 70
Study 23707331 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa (NS) 500 mg capsule twice daily for nine weeks
Number of subjects: 40
Study 23707331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21912062 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole therapy for 12 weeks preoperatively and 12 weeks postoperatively
Number of subjects: 72
Study 21912062 — intervention group
Group type: COMPARATOR
Intervention: No preoperative albendazole therapy (control group)
Number of subjects: 72
Study 18257813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (various dosages)
Number of subjects: 0
Study 18257813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16618292 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral pulse palpation
Number of subjects: 40
Study 16618292 — intervention group
Group type: COMPARATOR
Intervention: Brachial pulse palpation
Number of subjects: 40
Study 16618292 — intervention group
Group type: COMPARATOR
Intervention: Carotid pulse palpation
Number of subjects: 40
Study 12945071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox-2 inhibitors
Number of subjects: 0
Study 10901741 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic core needle biopsy
Number of subjects: 0
Study 10901741 — intervention group
Group type: EXPERIMENTAL
Intervention: Total mastectomy
Number of subjects: 0
Study 10901741 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving approach
Number of subjects: 0
Study 8884409 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemostatic pause sequence (1.5 min inactivity with gauze swabs)
Number of subjects: 101
Study 8884409 — intervention group
Group type: COMPARATOR
Intervention: No pause sequence (no inactivity period)
Number of subjects: 101
Study 1428568 — intervention group
Group type: EXPERIMENTAL
Intervention: timolol
Number of subjects: 8
Study 1428568 — intervention group
Group type: COMPARATOR
Intervention: betaxolol
Number of subjects: 8
Study 6722065 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐oestradiol and norethisterone acetate (Group A, n = 22)
Number of subjects: 69
Study 6722065 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐oestradiol plus oestriol and norethisterone acetate (Group B, n = 20)
Number of subjects: 69
Study 6722065 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C, n = 23)
Number of subjects: 69
Study 31207169 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasinumab (1 mg, 3 mg, 6 mg, or 9 mg) every 4 weeks for 16 weeks
Number of subjects: 421
Study 31207169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 31207169 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasinumab
Number of subjects: 421
Study 31207169 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasinumab (6 mg)
Number of subjects: 421
Study 29944580 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnoy's solution
Number of subjects: 130
Study 29944580 — intervention group
Group type: EXPERIMENTAL
Intervention: Revision group (formalin specimens immersed in Carnoy's solution)
Number of subjects: 130
Study 29944580 — intervention group
Group type: COMPARATOR
Intervention: Formalin
Number of subjects: 130
Study 26084569 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 36
Study 26084569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no resistance training)
Number of subjects: 36
Study 24767264 — intervention group
Group type: EXPERIMENTAL
Intervention: PNEIMED training (30 h over four days)
Number of subjects: 125
Study 24767264 — intervention group
Group type: EXPERIMENTAL
Intervention: PNEIMED training
Number of subjects: 125
Study 24767264 — intervention group
Group type: COMPARATOR
Intervention: Non-meditating control group
Number of subjects: 125
Study 23131368 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative intervention of acupressure and interactive multimedia of visual health instruction (ACIMU)
Number of subjects: 287
Study 23131368 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure (AC) alone
Number of subjects: 287
Study 23131368 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 287
Study 20678893 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated patch (lidocaine 70 mg/tetracaine 70 mg)
Number of subjects: 250
Study 20678893 — intervention group
Group type: COMPARATOR
Intervention: Unheated patch (lidocaine 70 mg/tetracaine 70 mg)
Number of subjects: 250
Study 17885347 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy treatment
Number of subjects: 346
Study 15844579 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG‐SPN intramuscular injection (1ml, once every two days for 5 weeks)
Number of subjects: 96
Study 15844579 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid nasal spray (once a day for 5 weeks)
Number of subjects: 96
Study 15844579 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of BCG‐SPN and corticosteroid nasal spray (as above for 5 weeks)
Number of subjects: 96
Study 12460131 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment approaches (5 types)
Number of subjects: 0
Study 12460131 — intervention group
Group type: COMPARATOR
Intervention: Outpatient drug-free programs for adults (previous DATCAP results)
Number of subjects: 0
Study 9799979 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 micrograms clonidine intraspinally
Number of subjects: 45
Study 9799979 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 micrograms clonidine intraspinally
Number of subjects: 45
Study 9799979 — intervention group
Group type: COMPARATOR
Intervention: 80 mg mepivacaine 4% only
Number of subjects: 45
Study 7648654 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (rTPA)
Number of subjects: 1043
Study 7648654 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1043
Study 7648654 — intervention group
Group type: EXPERIMENTAL
Intervention: rTPA with immediate PTCA
Number of subjects: 1043
Study 7648654 — intervention group
Group type: EXPERIMENTAL
Intervention: rTPA without additional intervention
Number of subjects: 1043
Study 7648654 — intervention group
Group type: EXPERIMENTAL
Intervention: comparative rTPA group
Number of subjects: 1043
Study 7648654 — intervention group
Group type: EXPERIMENTAL
Intervention: rTPA and immediate PTCA
Number of subjects: 1043
Study 7648654 — intervention group
Group type: EXPERIMENTAL
Intervention: rTPA group without PTCA
Number of subjects: 1043
Study 2503375 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil and thiopentone for induction, followed by alfentanil‐N2O/O2 (60%/40%) for maintenance
Number of subjects: 40
Study 2503375 — intervention group
Group type: COMPARATOR
Intervention: enflurane‐N2O/O2 (60%/40%) for maintenance
Number of subjects: 40
Study 358713 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin (5000 U) administered 2 hours before surgery and every 8 hours for 6 days.
Number of subjects: 144
Study 358713 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections administered to 47 operated patients.
Number of subjects: 144
Study 30489119 — intervention group
Group type: EXPERIMENTAL
Intervention: act-extraverted intervention
Number of subjects: 147
Study 30489119 — intervention group
Group type: COMPARATOR
Intervention: sham (active control) intervention
Number of subjects: 147
Study 30489119 — intervention group
Group type: COMPARATOR
Intervention: contact control condition
Number of subjects: 147
Study 30489119 — intervention group
Group type: EXPERIMENTAL
Intervention: dispositional extraversion
Number of subjects: 147
Study 28100253 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPO
Number of subjects: 64
Study 28100253 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 64
Study 25034442 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleogel-S10 ointment containing 10% birch bark extract
Number of subjects: 24
Study 25034442 — intervention group
Group type: COMPARATOR
Intervention: Control (intraindividual control, untreated half of the wound)
Number of subjects: 24
Study 23934375 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression
Number of subjects: 70
Study 23934375 — intervention group
Group type: EXPERIMENTAL
Intervention: Stockings
Number of subjects: 70
Study 23934375 — intervention group
Group type: COMPARATOR
Intervention: Short-stretch bandages
Number of subjects: 70
Study 20927554 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred preemptive lamivudine upon viremic surge (Group I)
Number of subjects: 45
Study 20927554 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic lamivudine (Group 2)
Number of subjects: 45
Study 19559142 — intervention group
Group type: EXPERIMENTAL
Intervention: Online calcium quiz
Number of subjects: 140
Study 19559142 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed calcium food frequency questionnaire
Number of subjects: 140
Study 19559142 — intervention group
Group type: COMPARATOR
Intervention: 3-day diet record
Number of subjects: 140
Study 17348463 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (as a second antiplatelet drug)
Number of subjects: 65
Study 17348463 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy without clopidogrel
Number of subjects: 65
Study 15968162 — intervention group
Group type: EXPERIMENTAL
Intervention: Antireflection (AR) film on displays
Number of subjects: 7
Study 15968162 — intervention group
Group type: COMPARATOR
Intervention: No antireflection (AR) film on displays
Number of subjects: 7
Study 11771654 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 7705
Study 11771654 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 7705
Study 11771654 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (any dose)
Number of subjects: 7705
Study 11771654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study 9829138 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-visit treatment program
Number of subjects: 162
Study 8135557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (2 mg/kg)
Number of subjects: 70
Study 8135557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 8135557 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (0.15 mg/kg every 30 minutes for the first three hours)
Number of subjects: 70
Study 8135557 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (5 mg every one to four hours as needed)
Number of subjects: 70
Study 2683917 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group physicians attended a 2-hour multimedia educational session and received four functional status reports on each of their study patients over a 1-year period.
Number of subjects: 510
Study 2683917 — intervention group
Group type: COMPARATOR
Intervention: Control group physicians received no education and no functional status feedback.
Number of subjects: 510